Oncogenic osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient

被引:6
作者
Dupond, JL
Magy, N
Mahammedi, M
Prie, D
Gil, H
Meaux-Ruault, N
Kantelip, B
机构
[1] Hop Jean Minjoz, Serv Med Interne, F-25030 Besancon, France
[2] Hop Xavier Bichat, Dept Physiol, F-75018 Paris, France
[3] Hop Jean Minjoz, Anat Pathol Lab, F-25030 Besancon, France
来源
REVUE DE MEDECINE INTERNE | 2005年 / 26卷 / 03期
关键词
oncogenic osteomalacia; hypophophatemia; phosphatonins; FGF-23; phosphaturic mesenchymal tumors; paraneoplastic syndrome;
D O I
10.1016/j.revmed.2004.11.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. - Oncogenic osteomalacia (00) is a rare paraneoplastic syndrome characterized by severe hypophosphatemia induced by phosphaturic factors which are secreted by some tumors of mesenchymal origin. Fibroblast Growth Factor 23 (FGF-23) belongs to this family. Measurement of FGF-23 might improve the diagnosis of OO. Exegesis. - We report the case of 71-year-old Caucasian man who had a history of severe osteomalacia with multiples fractures and extreme hypophosphatemia with hyperphosphaturia and normal serum calcium level. Serum FGF-23 was 199 RU/ml (N < 100 RU/ml). The tumor, detected by F-18 FDG PET/CT SCAN was localized in the mandible. Surgical removal of the tumor relieved all symptoms with normalization of serum phosphate levels within 3 days after surgery. Conclusion. - We conclude that FGF-23 measurement is likely to be of considerable importance for facilitating early diagnosis of OO. (c) 2004 Elsevier SAS. Tons droits reserves.
引用
收藏
页码:238 / 241
页数:4
相关论文
共 23 条
[1]   Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent [J].
Berndt, T ;
Craig, TA ;
Bowe, AE ;
Vassiliadis, J ;
Reczek, D ;
Finnegan, R ;
De Beur, SMJ ;
Schiavi, SC ;
Kumar, R .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (05) :785-794
[2]  
Beyer T, 2004, J NUCL MED, V45, p25S
[3]   FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate [J].
Bowe, AE ;
Finnegan, R ;
de Beur, SMJ ;
Cho, J ;
Levine, MA ;
Kumar, R ;
Schiavi, SC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 284 (04) :977-981
[4]   Oncogenic osteomalacia - A complex dance of factors [J].
Carpenter, TO .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1705-1708
[5]  
Casari S, 2003, CLIN EXP RHEUMATOL, V21, P493
[6]  
DREZNER MK, 1999, PRIMER METABOLIC BON, P33
[7]   Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity - An analysis of 32 cases and a comprehensive review of the literature [J].
Folpe, AL ;
Fanburg-Smith, JC ;
Billings, SD ;
Bisceglia, M ;
Bertoni, F ;
Cho, JY ;
Econs, MJ ;
Inwards, CY ;
de Beur, SMJ ;
Mentzel, T ;
Montgomery, E ;
Michal, M ;
Miettinen, M ;
Mills, SE ;
Reith, JD ;
O'Connell, JX ;
Rosenberg, AE ;
Rubin, BP ;
Sweet, DE ;
Vinh, TN ;
Wold, LE ;
Wehrli, BM ;
White, FKE ;
Zaino, RJ ;
Weiss, SW .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (01) :1-30
[8]   Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. [J].
Jonsson, KB ;
Zahradnik, R ;
Larsson, T ;
White, KE ;
Sugimoto, T ;
Imanishi, Y ;
Yamamoto, T ;
Hampson, G ;
Koshiyama, H ;
Ljunggren, Ö ;
Oba, K ;
Yang, IM ;
Miyauchi, A ;
Econs, MJ ;
Lavigne, J ;
Jüppner, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1656-1663
[9]  
KOEGER AC, 1985, PRESSE MED, V14, P1747
[10]  
Nguyen BD, 1999, CLIN NUCL MED, V24, P130